Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation 

Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain

However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community

In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy 

The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022 

In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms

Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent 

Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations

The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor

Blocking the tyrosine kinase cell-cycle progression regulator WEE1 may help to reinstate tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors